AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16575844 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertive Community Treatment (ACT)
Number of subjects: 0
Study 16575844 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Treatment (IT)
Number of subjects: 0
Study 16575844 — intervention group
Group type: COMPARATOR
Intervention: Standard Treatment
Number of subjects: 0
Study 11834107 — intervention group
Group type: EXPERIMENTAL
Intervention: Zone diet
Number of subjects: 8
Study 9869772 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryopreserved platelets
Number of subjects: 73
Study 9869772 — intervention group
Group type: COMPARATOR
Intervention: Liquid-preserved platelets
Number of subjects: 73
Study 8676535 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-hour enteral nutrition (EN) at 2 kcal/min for 6 hours
Number of subjects: 6
Study 8676535 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-hour enteral nutrition (EN) at 1 kcal/min for 12 hours
Number of subjects: 6
Study 8676535 — intervention group
Group type: COMPARATOR
Intervention: Oral meal
Number of subjects: 6
Study 1611137 — intervention group
Group type: EXPERIMENTAL
Intervention: ponalrestat 600 mg per day
Number of subjects: 62
Study 1611137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 6436633 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheelchair exercise
Number of subjects: 10
Study 6436633 — intervention group
Group type: COMPARATOR
Intervention: Arm cranking exercise
Number of subjects: 10
Study 31116891 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous oxytocin (4 µg/4 ml saline)
Number of subjects: 30
Study 31116891 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous lidocaine 1% (4 ml)
Number of subjects: 30
Study 31116891 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 30
Study 29740733 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental voucher condition (residential mobility out of public housing into lower poverty neighborhoods)
Number of subjects: 2829
Study 29740733 — intervention group
Group type: COMPARATOR
Intervention: Control group (remaining in public housing)
Number of subjects: 2829
Study 29740733 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental voucher condition
Number of subjects: 2829
Study 26265099 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (HDMTX) treatment
Number of subjects: 30
Study 24865255 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-thymocyte globulin (ATG) during induction phase of immunosuppression (IPI)
Number of subjects: 49
Study 24865255 — intervention group
Group type: COMPARATOR
Intervention: Standard induction therapy
Number of subjects: 49
Study 22959283 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil + Choline Alphoscerate
Number of subjects: 91
Study 22959283 — intervention group
Group type: COMPARATOR
Intervention: Donepezil + Placebo
Number of subjects: 91
Study 20456026 — intervention group
Group type: EXPERIMENTAL
Intervention: Packable composite (Filtek P60)
Number of subjects: 80
Study 20456026 — intervention group
Group type: EXPERIMENTAL
Intervention: Packable composite (Filtek P60) with flowable composite (Filtek Z350) as liner
Number of subjects: 80
Study 20456026 — intervention group
Group type: COMPARATOR
Intervention: Control group (Packable composite alone)
Number of subjects: 80
Study 20456026 — intervention group
Group type: EXPERIMENTAL
Intervention: Water storage and thermocycling
Number of subjects: 80
Study 17655773 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic Voting System (EVS)
Number of subjects: 127
Study 17655773 — intervention group
Group type: COMPARATOR
Intervention: Traditional teaching
Number of subjects: 127
Study 16088180 — intervention group
Group type: EXPERIMENTAL
Intervention: Dye-enhanced laser ablation (DLA) using a low-power diode laser at 10 W with ICG concentration of 0.5 mg/ml.
Number of subjects: 37
Study 16088180 — intervention group
Group type: COMPARATOR
Intervention: Cavitron ultrasonic surgical aspirator (CUSA)
Number of subjects: 37
Study 12391535 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane anaesthesia supplemented by 2 mg tropisetron
Number of subjects: 150
Study 12391535 — intervention group
Group type: COMPARATOR
Intervention: Propofol total intravenous anaesthesia (TIVA)
Number of subjects: 150
Study 10423055 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily morphine sulphate controlled-release suppositories
Number of subjects: 6
Study 10423055 — intervention group
Group type: COMPARATOR
Intervention: Once-daily morphine sulphate controlled-release suppositories
Number of subjects: 6
Study 7582383 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methylergometrine (0.125 mg)
Number of subjects: 12
Study 7582383 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous methylergometrine (0.200 mg)
Number of subjects: 12
Study 1648886 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin administration
Number of subjects: 12
Study 1648886 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1648886 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 12
Study 6138084 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg midazolam
Number of subjects: 12
Study 6138084 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg oxazepam
Number of subjects: 12
Study 6138084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 30968123 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-based, ready-to-use supplementary food (RUSF)
Number of subjects: 286
Study 30968123 — intervention group
Group type: EXPERIMENTAL
Intervention: Special corn-soy blend 'plus plus' (CSB++)
Number of subjects: 286
Study 30968123 — intervention group
Group type: EXPERIMENTAL
Intervention: Locally processed, fortified flour (MI)
Number of subjects: 286
Study 30968123 — intervention group
Group type: EXPERIMENTAL
Intervention: Locally milled flours plus oil, sugar, and micronutrient powder (LMF)
Number of subjects: 286
Study 30968123 — intervention group
Group type: COMPARATOR
Intervention: Recovery status
Number of subjects: 286
Study 28722167 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted autogenic drainage (AAD) with standard nursing care
Number of subjects: 29
Study 28722167 — intervention group
Group type: COMPARATOR
Intervention: Standard nursing care
Number of subjects: 29
Study 28722167 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted autogenic drainage (AAD)
Number of subjects: 29
Study 26884049 — intervention group
Group type: EXPERIMENTAL
Intervention: self-guided internet-based stress management intervention (iSMI)
Number of subjects: 264
Study 26884049 — intervention group
Group type: COMPARATOR
Intervention: wait-list control group (WLC)
Number of subjects: 264
Study 24563519 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplementation (combined selenium only and selenium + vitamin E arms)
Number of subjects: 3117
Study 24563519 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (alone)
Number of subjects: 3117
Study 24563519 — intervention group
Group type: COMPARATOR
Intervention: No supplementation (baseline selenium status)
Number of subjects: 3117
Study 21760499 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen ER 1300 mg
Number of subjects: 610
Study 21760499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 610
Study 19250753 — intervention group
Group type: EXPERIMENTAL
Intervention: Partner reflection condition
Number of subjects: 29
Study 19250753 — intervention group
Group type: COMPARATOR
Intervention: Cross-sex friend reflection condition
Number of subjects: 29
Study 17723128 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot exercises against increased resistance
Number of subjects: 21
Study 17723128 — intervention group
Group type: COMPARATOR
Intervention: Sitting motionless with feet not touching the floor
Number of subjects: 21
Study 17723128 — intervention group
Group type: COMPARATOR
Intervention: Immobility of seated subjects
Number of subjects: 21
Study 17723128 — intervention group
Group type: COMPARATOR
Intervention: Airline-recommended activities and foot exercises
Number of subjects: 21
Study 17723128 — intervention group
Group type: COMPARATOR
Intervention: Foot exercises against moderate resistance
Number of subjects: 21
Study 16022852 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg of DMPA from a multidose vial (400 mg/mL)
Number of subjects: 95
Study 16022852 — intervention group
Group type: COMPARATOR
Intervention: 150 mg of DMPA from a single-unit-dose vial (150 mg/mL)
Number of subjects: 95
Study 16022852 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidose group
Number of subjects: 95
Study 16022852 — intervention group
Group type: COMPARATOR
Intervention: Unit-dose group
Number of subjects: 95
Study 12221311 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention (culturally sensitive group program in addition to individual supportive therapy)
Number of subjects: 48
Study 12221311 — intervention group
Group type: COMPARATOR
Intervention: Individual supportive therapy (control group)
Number of subjects: 48
Study 9697820 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (40 mg twice daily)
Number of subjects: 29
Study 9697820 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 9697820 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (40 mg twice daily) with L‐NMMA (4 micromol/min)
Number of subjects: 29
Study 8590530 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (10-40 mg/day)
Number of subjects: 800
Study 8590530 — intervention group
Group type: COMPARATOR
Intervention: Fibrate therapy (gemfibrozil 900 mg/day, ciprofibrate 100 mg/day, bezafibrate 400 mg/day, fenofibrate 300 or 400 mg/day)
Number of subjects: 800
Study 8590530 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 800
Study 8590530 — intervention group
Group type: COMPARATOR
Intervention: Fibrate therapy
Number of subjects: 800
Study 1699814 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost
Number of subjects: 103
Study 1699814 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 394300 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (0.6 mg) and meperidine (1 mg/kg body weight)
Number of subjects: 100
Study 394300 — intervention group
Group type: COMPARATOR
Intervention: Control group (benzocaine and intravenous diazepam only)
Number of subjects: 100
Study 31108564 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescribing recommendations generated by a physician using STRIP Assistant
Number of subjects: 124
Study 31108564 — intervention group
Group type: COMPARATOR
Intervention: Usual care medication review (Control)
Number of subjects: 124
Study 28771379 — intervention group
Group type: EXPERIMENTAL
Intervention: VR plus standard treatment group
Number of subjects: 50
Study 28771379 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (ST) group
Number of subjects: 50
Study 26461465 — intervention group
Group type: EXPERIMENTAL
Intervention: One-stage full-mouth disinfection (FMD)
Number of subjects: 78
Study 26461465 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing per quadrant (SRP-Q)
Number of subjects: 78
Study 23386261 — intervention group
Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir plus abacavir/lamivudine
Number of subjects: 95
Study 23386261 — intervention group
Group type: COMPARATOR
Intervention: lopinavir/ritonavir monotherapy
Number of subjects: 95
Study 22260837 — intervention group
Group type: EXPERIMENTAL
Intervention: 3d triple therapy (rabeprazole 10mg + furazolidone 100mg + clarithromycin 250mg for 3 days)
Number of subjects: 116
Study 22260837 — intervention group
Group type: EXPERIMENTAL
Intervention: 5d triple therapy (rabeprazole 10mg + furazolidone 100mg + clarithromycin 250mg for 5 days)
Number of subjects: 116
Study 22260837 — intervention group
Group type: COMPARATOR
Intervention: 7d triple therapy (rabeprazole 10mg + furazolidone 100mg + clarithromycin 250mg for 7 days)
Number of subjects: 116
Study 19711845 — intervention group
Group type: EXPERIMENTAL
Intervention: Viferon (suppositories of human recombinant interferon alfa‐2)
Number of subjects: 0
Study 19711845 — intervention group
Group type: COMPARATOR
Intervention: Arbidol (reference drug)
Number of subjects: 0
Study 17557257 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic evaluations of health interventions in nephrology
Number of subjects: 0
Study 15465451 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task condition (visuomotor tracking task + somatosensory oddball task)
Number of subjects: 0
Study 15465451 — intervention group
Group type: COMPARATOR
Intervention: Oddball-only condition
Number of subjects: 0
Study 15465451 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task condition with unpredictable tracking direction
Number of subjects: 0
Study 15465451 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task condition with fastest tracking speed
Number of subjects: 0
Study 15465451 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task condition with predictable tracking direction
Number of subjects: 0
Study 11219471 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan (40 mg titrated to 80 mg titrated to 120 mg)
Number of subjects: 533
Study 11219471 — intervention group
Group type: COMPARATOR
Intervention: Atenolol (50 mg titrated to 100 mg)
Number of subjects: 533
Study 11219471 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 533
Study 11219471 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 533
Study 9482510 — intervention group
Group type: EXPERIMENTAL
Intervention: Buflomedil 400 mg intravenous daily for 5 days
Number of subjects: 39
Study 9482510 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl)
Number of subjects: 39
Study 8037262 — intervention group
Group type: EXPERIMENTAL
Intervention: Hallucinated 'voices'
Number of subjects: 4
Study 8037262 — intervention group
Group type: COMPARATOR
Intervention: Comparison speakers
Number of subjects: 4
Study 3132275 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (30 micrograms/kg intravenous)
Number of subjects: 10
Study 4895338 — intervention group
Group type: EXPERIMENTAL
Intervention: Methoxyflurane
Number of subjects: 0
Study 4895338 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide
Number of subjects: 0
Study 31550290 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal suggestion indicating less painful stimuli (green or red colour)
Number of subjects: 56
Study 31550290 — intervention group
Group type: COMPARATOR
Intervention: No verbal suggestion (control group)
Number of subjects: 56
Study 29197414 — intervention group
Group type: EXPERIMENTAL
Intervention: IBBIS mental health care integrated with IBBIS vocational rehabilitation
Number of subjects: 603
Study 29197414 — intervention group
Group type: EXPERIMENTAL
Intervention: IBBIS mental health care and standard vocational rehabilitation
Number of subjects: 603
Study 29197414 — intervention group
Group type: COMPARATOR
Intervention: Standard mental health care and standard vocational rehabilitation
Number of subjects: 603
Study 26377553 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity in daily living
Number of subjects: 74
Study 23929355 — intervention group
Group type: EXPERIMENTAL
Intervention: multifaceted intervention: team‐based supported employment, systematic medication management, and other behavioral health services
Number of subjects: 2059
Study 23929355 — intervention group
Group type: COMPARATOR
Intervention: usual services (control group)
Number of subjects: 2059
Study 23929355 — intervention group
Group type: EXPERIMENTAL
Intervention: multifaceted intervention
Number of subjects: 2059
Study 20807305 — intervention group
Group type: EXPERIMENTAL
Intervention: Short compression with QuikClot® Interventional™ pad (15 minutes, group 1)
Number of subjects: 120
Study 20807305 — intervention group
Group type: EXPERIMENTAL
Intervention: Short compression (15 minutes, group 2)
Number of subjects: 120
Study 20807305 — intervention group
Group type: COMPARATOR
Intervention: Conventional prolonged compression (2 hours, group 3)
Number of subjects: 120
Study 18328608 — intervention group
Group type: EXPERIMENTAL
Intervention: Korsakoff patients with additional processing and response time, additional explanation, and explicit encouragement
Number of subjects: 2
Study 18328608 — intervention group
Group type: COMPARATOR
Intervention: Korsakoff patients without additional support
Number of subjects: 2
Study 18328608 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 2
Study 16490581 — intervention group
Group type: EXPERIMENTAL
Intervention: FSC 220/42 microg HFA (2 inhalations of FSC 110/21 microg)
Number of subjects: 365
Study 16490581 — intervention group
Group type: COMPARATOR
Intervention: FP 220 microg CFC (2 inhalations of FP 110 microg)
Number of subjects: 365
Study 16490581 — intervention group
Group type: COMPARATOR
Intervention: SAL 42 microg CFC (2 inhalations of 21 microg)
Number of subjects: 365
Study 16490581 — intervention group
Group type: COMPARATOR
Intervention: PLA HFA (2 inhalations of PLA)
Number of subjects: 365
Study 16490581 — intervention group
Group type: EXPERIMENTAL
Intervention: FSC
Number of subjects: 365
Study 16490581 — intervention group
Group type: COMPARATOR
Intervention: FP
Number of subjects: 365
Study 16490581 — intervention group
Group type: COMPARATOR
Intervention: SAL
Number of subjects: 365
Study 16490581 — intervention group
Group type: COMPARATOR
Intervention: PLA
Number of subjects: 365
Study 12641499 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg
Number of subjects: 24
Study 12641499 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg
Number of subjects: 24
Study 12641499 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg
Number of subjects: 24
Study 12641499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 10769552 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 ppm inhaled nitric oxide
Number of subjects: 15
Study 10769552 — intervention group
Group type: COMPARATOR
Intervention: 5 ppm inhaled nitric oxide
Number of subjects: 15
Study 9745813 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic steroid therapy
Number of subjects: 41
Study 9745813 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic antibiotic therapy
Number of subjects: 41
Study 8452185 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of fleroxacin orally
Number of subjects: 2
Study 8452185 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of fleroxacin intravenously
Number of subjects: 2
Study 8452185 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose adjustment recommended for patients with renal disease (GFR < 40 mL/min)
Number of subjects: 2
Study 3524668 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS
Number of subjects: 150
Study 3524668 — intervention group
Group type: COMPARATOR
Intervention: TENS placebo
Number of subjects: 150
Study 27382968 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental Agility and Psychological Strength training (4-hour resilience training intervention)
Number of subjects: 45
Study 27382968 — intervention group
Group type: COMPARATOR
Intervention: Training as Usual (TAU)
Number of subjects: 45
Study 24676365 — intervention group
Group type: EXPERIMENTAL
Intervention: Apple
Number of subjects: 30
Study 24676365 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinach
Number of subjects: 30
Study 24676365 — intervention group
Group type: EXPERIMENTAL
Intervention: Apple + Spinach
Number of subjects: 30
Study 24676365 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study 22715865 — intervention group
Group type: EXPERIMENTAL
Intervention: ACAT-initiated pharmacist home medicines review (APHMR)
Number of subjects: 80
Study 22715865 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist review of ACAT files
Number of subjects: 80
Study 22715865 — intervention group
Group type: COMPARATOR
Intervention: ACAT usual care
Number of subjects: 80
Study 22715865 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback from GPs on pharmacist medication reviews
Number of subjects: 80
Study 22715865 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient feedback on pharmacist home visits
Number of subjects: 80
Study 22715865 — intervention group
Group type: EXPERIMENTAL
Intervention: ACAT clinician feedback on pharmacist-led medication review
Number of subjects: 80
Study 20185746 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 2685
Study 20185746 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 2685
Study 20185746 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2685
Study 18705531 — intervention group
Group type: EXPERIMENTAL
Intervention: Val/HCTZ 320/25 mg
Number of subjects: 2702
Study 18705531 — intervention group
Group type: EXPERIMENTAL
Intervention: Val/HCTZ 320/12.5 mg
Number of subjects: 2702
Study 18705531 — intervention group
Group type: COMPARATOR
Intervention: Val 320 mg
Number of subjects: 2702
Study 16581420 — intervention group
Group type: EXPERIMENTAL
Intervention: SA60AT single‐piece IOL
Number of subjects: 40
Study 16581420 — intervention group
Group type: COMPARATOR
Intervention: MA60AC 3‐piece IOL
Number of subjects: 40
Study 16581420 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SA60AT and MA60AC
Number of subjects: 40
Study 12518369 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (L-AmB) 3 mg/kg intravenously 3 times per week
Number of subjects: 139
Study 12518369 — intervention group
Group type: COMPARATOR
Intervention: Combination of fluconazole (200 mg orally every 12 hours) and itraconazole (200 mg orally every 12 hours)
Number of subjects: 139
Study 12518369 — intervention group
Group type: EXPERIMENTAL
Intervention: L-AmB
Number of subjects: 139
Study 12518369 — intervention group
Group type: COMPARATOR
Intervention: F+I
Number of subjects: 139
Study 10685588 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-down bed rest (HDBR)
Number of subjects: 6
Study 10685588 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-HDBR supine position
Number of subjects: 6
Study 10685588 — intervention group
Group type: COMPARATOR
Intervention: Head-up tilt (HUT) test before HDBR
Number of subjects: 6
Study 10685588 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-up tilt (HUT) test after HDBR
Number of subjects: 6
Study 9337600 — intervention group
Group type: EXPERIMENTAL
Intervention: self‐exposure and cognitive restructuring
Number of subjects: 20
Study 9337600 — intervention group
Group type: COMPARATOR
Intervention: progressive relaxation training
Number of subjects: 20